Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Gene therapy for ocular hypertension using hfCas13d-mediated mRNA targeting

1 Jun 2025

Abstract excerpt

Abstract Glaucoma is a major global cause of irreversible vision loss. It is marked by elevated intraocular pressure (IOP) and the loss of retinal ganglion cells (RGC). While there are medical and surgical therapies for glaucoma aiming to reduce aqueous humor production or enhance its drainage, these treatments are often inadequate for effectively managing the disease. In this study, we developed a targeted...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Glaucoma and retinal disorders
Share to Retinal Development and Disorders
Share to Retinal Diseases and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40575705
DOI: 10.1093/pnasnexus/pgaf168

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Gene therapy for ocular hypertension using hfCas13d-mediated mRNA targetingPMID 40575705Read ↗

CRISPR-Cas9-mediated deletion of carbonic anhydrase 2 in the ciliary body to treat glaucomaSemantic proximity Read ↗

Gene Therapy for Glaucoma by Ciliary Body Aquaporin 1 Disruption Using CRISPR-Cas9Semantic proximity Read ↗

CRISPR-CasRx-mediated disruption of Aqp1/Adrb2/Rock1/Rock2 genes reduces intraocular pressure and retinal ganglion cell damage in miceSemantic proximity Read ↗

Inducible scAAV2.GRE.MMP1 lowers IOP long-term in a large animal model for steroid-induced glaucoma gene therapySemantic proximity Read ↗

Using CRISPR Interference as a Therapeutic Approach to Treat TGFβ2-Induced Ocular Hypertension and GlaucomaSemantic proximity Read ↗

Lentiviral mediated delivery of CRISPR/Cas9 reduces intraocular pressure in a mouse model of myocilin glaucomaSemantic proximity Read ↗

Lentiviral mediated delivery of CRISPR/Cas9 reduces intraocular pressure in a mouse model of myocilin glaucomaSemantic proximity Read ↗

Topical application of Cas9 ribonucleoproteins inhibits corneal neovascularization in a mouse model of alkali burn injurySemantic proximity Read ↗

MAGNETICALLY STEERED CELL THERAPY FOR REDUCTION OF INTRAOCULAR PRESSURE AS A TREATMENT STRATEGY FOR OPEN-ANGLE GLAUCOMASemantic proximity Read ↗

Gene Therapy Targeting Glaucoma: Where Are We?Semantic proximity Read ↗

Transduction optimization of AAV vectors for human gene therapy of glaucoma and their reversed cell entry characteristicsSemantic proximity Read ↗

Matrix metalloproteinase-3 (MMP-3)–mediated gene therapy for glaucomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.